PIK3CA and neoplasm: Our results suggest that, a) mutant KRAS, by synergistic engagement of MEK and PI3K pathways, maintains MUC2 expression and b) dual inhibition of MEK and PI3K is more effective in reducing tumor cell viability in vitro and in vivo than single agent treatment.